Diagnostic Efficiency of Different Screening Indexes for Primary Aldosteronism

LI Yuan-mei, WANG Wen, LI Qian-rui, CHEN Tao, MO Dan, ZHANG Ting-ting, ZHOU Fang-li, REN Yan, TIAN Hao-ming

Abstract

To investigate the the feasibility and diagnostic efficiencyvalue of different screening indexesmethods for screening primary aldosteronism (PA).  Methods  The clinical data of 499 patients with PA and 479 patients with essential hypertension diagnosed from Jan. 2009 to Dec. 2018 were retrospectively analyzed. The diagnostic performance of different screening indexs was compared by plotting receiver operating characteristic curves (ROC).  Results  The area under the ROC curve (AUC) of the plasma aldosterone concentration (PAC) to plasma renin activity (PRA) ratio (ARR) was greater than that of the ratio of the upright PAC to the angiotensin Ⅱ (AT-Ⅱ) (AA2R), upright PRA, upright PAC, supine ARR, and lowest blood potassium (P<0.05). The AUC of logistic regression model was greater than that of upright ARR (96.3% vs. 94.6%, P<0.05). There was no significant difference in AUC between decision tree model and upright ARR (94.1% vs. 94.6%, P>0.05). In the test set, the AUC difference between the logistic regression model and the decision tree model was not statistically significant (96.3% vs. 94.1%, P > 0.05). The calibration curve of the logistic regression model is closer to the 45 ° line, and the consistency between the prediction probability and the actual probability of the logistic regression model is better than that of the decision tree model.  Conclusion  For the screening of PA, upright ARR seems to be the best single screening index, while AA2R (radioimmunoassay) is not recommended. The diagnostic efficacy of logistic regression model including upright PAC, PRA and lowest blood potassium is better than that of single upright ARR.

 

Keywords: Primary aldosteronism,.Screening, Diagnosis, Predicting model

 

Full Text:

PDF


References


FUNDER J W， CAREY R M， MANTERO F， et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab， 2016，101(5): 1889–1916.

MULATERO P， STOWASSER M， LOH K C， et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab，2004，89(3): 1045–1050.

ROSSI G P， BERNINI G， CALIUMI C， et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol，2006，48(11): 2293–2300.

EIDE I K， TORJESEN P A， DROLSUM A， et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens， 2004，22(11): 2217–2226.

WANG Z， CHEN Z， ZHANG L， et al. Status of hypertension in china: results from the china hypertension survey, 2012-2015. Circulation，2018， 137(22): 2344–2356.

MONTICONE S， D'ASCENZO F， MORETTI C， et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol，2018，6(1): 41–50.

STOWASSER M， AHMED A H， PIMENTA E， et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res，2012，44(3): 170–176.

YOUNG W F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf)，2007，66(5): 607–618.

. BAUDRAND R， GUARDA F J， FARDELLA C， et al. Continuum of renin-independent aldosteronism in normotension. Hypertension，2017， 69(5): 950–956.

YOUNG W F， Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med，2019，285(2): 126–148.

VAIDYA A， MULATERO P， BAUDRAND R， et al. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev，2018，39(6): 1057–1088. WOLLEY M J， STOWASSER M. New advances in the diagnostic workup of primary aldosteronism. J Endocr Soc，2017，1(3): 149–161.

POGLITSCH M. The AA2-ratio: improved screening for primary aldosteronism in hypertension. J Hypertens，2016，34: e270[2020-03-20].doi: 10.1097/01.hjh.0000492126.92947.fb.

POGLITSCH M， AHMED A H， RESL M， et al. The aa2-ratio: towards improved screening for primary aldosteronism in hypertension. J Hypertension，2016，34: e400[2020-03-20].doi: 10.1097/01.hjh.0000501024. 99460.c9.

BURRELLO J， BUFFOLO F， DOMENIG O， et al. Renin-angiotensin-aldosterone system Triple-A analysis for the screening of primary aldosteronism. Hypertension，2020，75(1): 163–172.

POULSEN K. Measurements of renin-angiotensin-aldosterone. Pharmacol Rev，1973，25(2): 249–257.

KONG A P S， CHOI C H， NG C M， et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab，2005，90(1): 72–78.

BARIGOU M， AH-KANG F， ORLOFF E， et al. Effect of postural changes on aldosterone to plasma renin ratio in patients with suspected secondary hypertension. Ann Cardiol Angeiol (Paris)，2015，64(3): 169–174.

KOBAYASHI H， ABE M， SOMA M， et al. Development and validation of subtype prediction scores for the workup of primary aldosteronism. J Hypertens，2018，36(11): 2269–2276.

HASHIMURA H， SHEN J， FULLER P J， et al. Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism. Clin Endocrinol (Oxf)，2018，89(3): 308–313.

KOBAYASHI H， HAKETA A， UENO T， et al. Scoring system for the diagnosis of bilateral primary aldosteronism in the outpatient setting before adrenal venous sampling. Clin Endocrinol (Oxf)，2017，86(4): 467–472.

KOCJAN T， JANEZ A， STANKOVIC M， et al. A new clinical prediction criterion accurately determines a subset of patients with bilateral primary aldosteronism before adrenal venous sampling. Endocr Pract，2016，22(5): 587–594.

VENOS E S， SO B， DIAS V C， et al. A clinical prediction score for diagnosing unilateral primary aldosteronism may not be generalizable. BMC Endocr Disord，2014，14: 94[2020-03-20]. http://doi.org/10.1186/ 1472-6823-14-94..

SZE W C， SOH L M， LAU J H， et al. Diagnosing unilateral primary aldosteronism—comparison of a clinical prediction score, computed tomography and adrenal venous sampling. Clin Endocrinol (Oxf)，2014， 81(1): 25–30.

ZHANG Y， NIU W， ZHENG F， et al. Identifying unilateral disease in chinese patients with primary aldosteronism by using a modified prediction score. J Hypertens，2017，35(12): 2486–2492.

NANBA K， TSUIKI M， NAKAO K， et al. A subtype prediction score for primary aldosteronism. J Hum Hypertens，2014，28(12): 716–720.

RIESTER A， FISCHER E， DEGENHART C， et al. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab，2014，99(6): E1035–E1039.

UMAKOSHI H， TSUIKI M， TAKEDA Y， et al. Significance of computed tomography and serum potassium in predicting subtype diagnosis of primary aldosteronism. J Clin Endocrinol Metab，2018， 103(3): 900–908.

XIAO L， JIANG Y， ZHANG C， et al. A novel clinical nomogram to predict bilateral hyperaldosteronism in chinese patients with primary aldosteronism. Clin Endocrinol (Oxf)，2019，90(6): 781–788.

VELEMA M S， LINSSEN E J M， HERMUS A R M M， et al. A prediction model for primary aldosteronism when the salt loading test is inconclusive. Endocr Connect，2018，7(12): 1308–1314.

YAMASHITA T， SHIMIZU S， KOYAMA M， et al. Screening of primary aldosteronism by clinical features and daily laboratory tests: combination of urine pH, sex, and serum K+. J Hypertens，2018，36(2): 326–334.


Refbacks

  • There are currently no refbacks.